Stock Trading Canary← Stock Trading Canary · All insider profiles
INSIDER PROFILE · LU
Analytical Bioventures S.C.A
S.E., CEO Dr. Gilles Martin
Profile key: lu|analytical bioventures s.c.a
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 167
- Purchases · 24M
- 240
- Average purchase
- €122,423
- Gross purchase value
- €29,381,522
- Last purchase
- 2026-10-21
- Completed 20D events
- 77.0
- Outcome status
- PASS
Latest company: EUROFINS SCIENTIFIC SE
Companies: EUROFINS SCIENTIFIC SE
Post-purchase outcomes
Benchmark-relative outcomes are available against STOXX Europe 600 (regional proxy).
- Excess return = stock return − STOXX Europe 600 (regional proxy) return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 81Established | 100.0% (81/81) | 61.7% (50/81) | +1.0% | +1.3% | -5.8% |
| 20D | 77Established | 100.0% (77/77) | 58.4% (45/77) | +3.2% | +2.9% | -9.8% |
| 60D | 64Established | 100.0% (64/64) | 71.9% (46/64) | +4.2% | +6.0% | -12.3% |
| 120D | 50Established | 100.0% (50/50) | 48.0% (24/50) | -0.6% | -0.1% | -12.8% |
Research patterns
- First purchase in 12M
- 2/81
- Large purchase ≥ €100k
- 72/81
- Cluster buying · 15D
- 7/81
- Buying the dip · ≥20% below prior 52W high
- 0/81
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.